In 2019, a phase 1/2a clinical trial reported that an AON construct targeting HTT gene was capable to reduce mutant HTT in cerebral spinal fluids in patients at early onset of HD.[184] Currently, two phase 3 trials (NCT03761849, NCT03842969) are being undertaken to evaluate the safety, efficacy, and tolerability of AON‐based drugs in HD patients. The gene discussed is HTT; the disease is Huntington disease.